首页> 外文期刊>The Journal of Urology >Re: Evaluation of a multi-herb supplement for erectile dysfunction: A randomized double-blind, placebo-controlled study
【24h】

Re: Evaluation of a multi-herb supplement for erectile dysfunction: A randomized double-blind, placebo-controlled study

机译:回复:评估多种草药补充剂对勃起功能障碍的作用:一项随机双盲,安慰剂对照研究

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Evidence is lacking for multi-ingredient herbal supplements claiming therapeutic effect in sexual dysfunction in men. We examined the safety and efficacy of VigRX Plus (VXP) - a proprietary polyherbal preparation for improving male sexual function, in a double blind, randomized placebo-controlled, parallel groups, multi-centre study. Methods: 78 men aged 25-50 years of age; suffering from mild to moderate erectile dysfunction (ED), participated in this study. Subjects were randomized to receive VXP or placebo at a dose of two capsules twice daily for 12 weeks. The international index of erectile function (IIEF) was the primary outcome measure of efficacy. Other efficacy measures were: Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS), Serum testosterone, Semen analysis, Investigator's Global assessment and Subjects' opinion. Results: In subjects receiving VXP, the IIEF-Erectile Function (EF) scores improved significantly as compared to placebo. After 12 weeks of treatment, the mean (sd) IIEF-EF score at baseline increased from 16.08 (2.87) to 25.08 (4.56) in the VXP group versus 15.86 (3.24) to 16.47 (4.25) in the placebo group (P < 0.0001). Similar results were observed in each of the remaining four domains of the IIEF (orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction).There was a significant difference for VXP versus placebo comparison of mean (sd) EDITS scores of patients: 82.31 (20.23) vs 36.78 (22.53) and partners: 82.75 (9.8) vs 18.50 (9.44); P < 0.001. Thirty-five out of 39 (90%) subjects from the VXP group and one (3%) from the placebo group wished to continue with the treatment they received. Investigator's global assessment rated VXP therapy as very good to excellent in more than 50% patients and placebo therapy as fair to good in about 25% of patients. Incidence of side effects and subject's rating for tolerability of treatment was similar in both groups. Conclusions: VigRX Plus was well tolerated and more effective than placebo in improving sexual function in men.
机译:背景:缺乏声称对男性性功能障碍具有治疗作用的多成分草药补品的证据。我们在双盲,随机安慰剂对照,平行组,多中心研究中,研究了VigRX Plus(VXP)(一种用于改善男性性功能的专有多草药制剂)的安全性和有效性。方法:78名年龄在25-50岁之间的男性;患有轻度至中度勃起功能障碍(ED)的患者参加了这项研究。受试者随机分为两组,每天两次,两次服用VXP或安慰剂,持续12周。国际勃起功能指数(IIEF)是疗效的主要指标。其他功效指标包括:勃起功能障碍治疗满意度清单(EDITS),血清睾丸激素,精液分析,研究者的总体评估和受试者的意见。结果:与安慰剂相比,接受VXP的受试者的IIEF-勃起功能(EF)得分明显提高。治疗12周后,VXP组的基线IIEF-EF平均值(sd)从16.08(2.87)增加到25.08(4.56),而安慰剂组从15.86(3.24)增加到16.47(4.25)(P <0.0001 )。在IIEF其余四个领域(性高潮功能,性欲,性交满意度和总体满意度)中都观察到了相似的结果.VXP与安慰剂比较患者的平均(sd)EDITS评分存在显着差异:82.31 (20.23)对36.78(22.53)和合作伙伴:82.75(9.8)对18.50(9.44); P <0.001。 VXP组的39名受试者中有35名(90%),安慰剂组有1名(3%)希望继续接受治疗。研究人员的全球评估将VXP治疗在50%以上的患者中认为是非常好至优秀,而安慰剂治疗在约25%的患者中认为是良好到良好。两组的副作用发生率和受试者对治疗耐受性的评分相似。结论:VigRX Plus在改善男性性功能方面具有良好的耐受性,并且比安慰剂有效。

著录项

  • 来源
    《The Journal of Urology》 |2013年第2期|共2页
  • 作者

    SeftelA.D.;

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 15:17:20

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号